• All
  • Primary Antibodies
  • Conjugated Antibodies for IF
  • Conjugated Antibodies for FC
  • Secondary Antibodies
  • Antibody Labeling KitsNew
  • ELISA Kits
  • IHC Kits
  • Magnetic Cell Separation Kits
  • Cytokines & Growth Factors
  • Neutralizing/activating Antibodies
  • Nanobody-based Reagents
  • Accessory Products and Kits
  • Fusion Proteins
×
×
Host
0
Species Reactivity
0
Species Reactivity
0
Conjugate
0
Conjugate
0
Compatible Species
0
Conjugate
0

NeutraKine® Noggin Monoclonal antibody

NeutraKine® Noggin Monoclonal Antibody for ELISA, Neutralization

Host / Isotype

Mouse / IgG1

Reactivity

Human

Applications

ELISA, Neutralization

Conjugate

Unconjugated

CloneNo.

2A11C1

Cat no : 69010-1-Ig

Synonyms

NeutraKine® Noggin, NOG, noggin, SYM1, SYNS1

Validation Data Gallery

Filter:
  • Neutralization experiment of NeutraKine® Noggin using NeutraKine® Noggin Monoclonal antibody (69010-1-Ig)

    Neutralization experiment of NeutraKine® Noggin using 69010-1-Ig

    Recombinant human Noggin (Cat.NO. HZ-1118) inhibits BMP-4 induced alkaline phosphate production (using pNPP as chromogenic substrate for detection) by ATDC5 in a dose dependent manner (blue curve, refer to bottom X-left Y). The activity of human Noggin (40 ng/mL HZ-1118) is neutralized by mouse anti-human Noggin monoclonal antibody 69010-1-Ig at serial dose (red curve, refer to top X-right Y). The ND50 is typically 5-20 μg/mL. The NeutraControl mouse anti-human Noggin monoclonal antibody 69510-1-Ig, generated from the same immunogen, could not neutralize human Noggin at the range of 0.0244-200 μg/mL(green curve, refer to top X-right Y).

  • ELISA experiment of Recombinant protein using NeutraKine® Noggin Monoclonal antibody (69010-1-Ig)

    ELISA experiment of Recombinant protein using 69010-1-Ig

    Indirect ELISA was carried out by coating recombinant Human Noggin (Cat.NO. HZ-1118) at 70 ng/well followed by blocking and adding serial diluted Noggin antibody 69010-1-Ig and 69510-1-Ig respectively. Signal was developed with TMB and stopped by H2SO4. Signal strength was measured by absorbance at 450 nm.

Neutralization

Product Information

69010-1-Ig targets NeutraKine® Noggin in ELISA, Neutralization applications and shows reactivity with Human samples.

Tested Reactivity Human
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen human Humankine Noggin protein HZ-1118
Full Name noggin
Gene Symbol Noggin
Gene ID (NCBI) 9241
RRIDAB_2882928
Conjugate Unconjugated
Form Lyophilized Powder
Purification MethodProtein G purification
Storage Buffer Sterile PBS.
Endotoxin<0.1 EU/μg
ReconstitutionThis product was lyophilized from a 0.2 μm filtered solution in PBS. Reconstitute at 1.0 mg/mL in sterile H2O before use.
Stability and StorageLyophilized antibodies are stable for 1 year from the date of receipt if stored between (-20°C) and (-80°C). Upon reconstitution we recommend that the solution can be stored at (4°C) for short term or at (-20°C) to (-80°C) for long term. Repeated freeze thaw cycles should be avoided with reconstituted products.

Background Information

Noggin is an extracellular polypeptide acting as an antagonist of bone morphogenetic proteins (BMPs) regulating embryonal development. Noggin inhibits activity of BMP-2, -4, -7, -13, and -14. Noggin is present extracellularly in the matrix or retained at the cell surface via interaction with heparin sulfate proteoglycans. In early development stages, Noggin is produced by the Spemann organizer, allowing dorsal-ventral patterning of BMPs (PMID: 8752214). Subsequently, Noggin is expressed by the notochord regulating BMP-4 signaling in neurogenesis. Additionally, Noggin is present during development in the dermal papilla, connective tissue of the hair follicle, lens, retina, and periocular mesenchyme, as well as in the mesoderm lineage regulating development of the bone, cartilage, and muscles.

This antibody can be used to neutralize the bioactivity of Noggin.

Protocols

Product Specific Protocols
FC protocol for NeutraKine® Noggin antibody 69010-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols